AbbVie (NYSE:ABBV) Shares Up 1.1% – What’s Next?

AbbVie Inc. (NYSE:ABBV) shot up 1.1% during trading on Thursday . The company traded as high as $219.68 and last traded at $219.13. 6,049,042 shares traded hands during trading, a decline of 6% from the average session volume of 6,402,746 shares. The stock had previously closed at $216.77.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ABBV shares. Hsbc Global Res lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Morgan Stanley raised their price objective on AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Daiwa Capital Markets raised AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price objective for the company in a research report on Thursday, August 7th. Guggenheim increased their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Finally, Wall Street Zen upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $236.57.

AbbVie Stock Down 0.1%

The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The firm has a market capitalization of $386.74 billion, a price-to-earnings ratio of 104.25, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The firm has a 50 day moving average price of $223.24 and a two-hundred day moving average price of $202.30.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie’s dividend payout ratio is currently 524.24%.

Insider Buying and Selling

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.25% of the stock is owned by company insiders.

Institutional Trading of AbbVie

A number of hedge funds have recently made changes to their positions in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in AbbVie by 44.1% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 487,025 shares of the company’s stock worth $111,854,000 after acquiring an additional 148,970 shares in the last quarter. Fiera Capital Corp grew its stake in AbbVie by 51.3% in the third quarter. Fiera Capital Corp now owns 164,617 shares of the company’s stock worth $38,115,000 after purchasing an additional 55,807 shares in the last quarter. Midland Wealth Advisors LLC increased its holdings in AbbVie by 7.1% in the third quarter. Midland Wealth Advisors LLC now owns 15,196 shares of the company’s stock valued at $3,518,000 after buying an additional 1,009 shares during the last quarter. Ontario Teachers Pension Plan Board acquired a new stake in AbbVie during the third quarter valued at approximately $54,585,000. Finally, Alpha Financial Partners LLC grew its position in shares of AbbVie by 10.6% in the 3rd quarter. Alpha Financial Partners LLC now owns 1,791 shares of the company’s stock worth $415,000 after acquiring an additional 172 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.